Interleukin-8 receptor antagonists

Abstract

This patent discloses diarylurea derivatives that are potent inhibitors of interleukin 8 (IL-8) binding as well as IL-8-mediated neutrophil chemotaxis and enzyme release. The claimed compounds would be expected to be useful in the treatment of IL-8-mediated inflammatory diseases. The compounds are reported to have binding IC₅₀ values ranging from < 1 - 45 mg/ml in a membrane binding assay.

• chemokine
• diarylurea
• interleukin-8